Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3336534 | 1.00 | HSD17B10 (0.39) | HSD17B10CHRM2CHRM1CHRM3HPGD | |
| SCHEMBL3338925 | 1.00 | HSD17B10 (0.39) | HSD17B10CHRM2CHRM1CHRM3HPGD | |
| Hydrochloric Acid SCHEMBL31160941 | 0.98 | HSD17B10 (0.38) | HSD17B10CHRM2CHRM1CHRM3HPGD | |
| SCHEMBL14196132 | 0.86 | HSD17B10 (0.38) | HSD17B10CHRM2CHRM1CHRM3HPGD | |
| SCHEMBL17910814 | 0.86 | HSD17B10 (0.38) | HSD17B10CHRM2CHRM1CHRM3HPGD | |
| SCHEMBL13944523 | 0.86 | HSD17B10 (0.38) | HSD17B10CHRM2CHRM1CHRM3HPGD | |
| SCHEMBL19063648 | 0.86 | HSD17B10 (0.38) | HSD17B10CHRM2CHRM1CHRM3HPGD | |
| SCHEMBL14196131 | 0.86 | HSD17B10 (0.38) | HSD17B10CHRM2CHRM1CHRM3HPGD | |
| SCHEMBL15943084 | 0.83 | CHRM2 (0.40) | HSD17B10CHRM2CHRM1CHRM3USP2 | |
| SCHEMBL21012791 | 0.83 | CHRM2 (0.40) | HSD17B10CHRM2CHRM1CHRM3USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7872010-B2 | Substituted diazabicycloalkane derivatives having affinity for nicotinic acetylcholine receptors | ABBOTT LABORATORIES (US) | 2011-01-18 | — | — | US | disclosed |
| US-20080275048-A1 | Substituted Diazabicycloalkane Derivates | ABBOTT LABORATORIES (US) | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275048-A1 | Substituted Diazabicycloalkane Derivates | CHRNA7, CHRNA1, CHRNA2 | HSD17B10 1520/4885CHRM2 31/4885CHRM1 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.